We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Test Significantly Reduces Mortality Associated With Staphylococcus aureus

By Biotechdaily staff writers
Posted on 22 May 2007
Clinical data have demonstrated significantly reduced mortality and hospital costs associated with staphylococcal bloodstream infections (BSIs) due to a new nucleic acid test.

The 2.5-hour fluorescence in-situ hybridization (FISH) assay uses fluorescence-labeled peptide nucleic acid (PNA) probes that target the species-specific ribosomal RNA (rRNA) in bacteria and yeast. More...
PNA FISH is a qualitative nucleic acid hybridization assay intended for identification of organisms from blood cultures. Results are visualized using fluorescence microscopy. Fluorescing cells indicate the target species, while no fluorescence indicates another species is present in the positive blood culture.

A group of infectious disease specialists, headed by Shmuel Shoham M.D. presented data from a study of AdvanDx, Inc.'s (Woburn, MA, USA) PNA FISH diagnostic test at the 2007 annual scientific Meeting of the Society for Healthcare Epidemiology of America. The study took place at the Washington Hospital Center (DC, USA), which is the largest hospital in the nation's capital and among the 25 largest hospitals in the United States.

During the study, 202 patients whose blood culture tested positive for Gram-positive cocci (indicating a staphylococcal bloodstream infection) were alternately assigned to a control, or intervention, group. In the intervention group, PNA FISH results and general organism information were relayed to the treating clinician via a call from a hospital liaison, whereas control group patients did not receive a call with PNA FISH results.

According to the study, reporting of PNA FISH results led to an 80% reduction in intensive care unit (ICU)-related mortality due to S aureus BSIs; median hospital cost-savings of US$19,441 per patient; and a 61% reduction in patients receiving antibiotics for coagulase-negative staphylococci (CNS), which is often a blood culture contaminant that leads to unnecessary antibiotic therapy even though the patient does not have a true bloodstream infection.

"Rapid delivery of PNA FISH data from the laboratory to clinicians was associated with reduced mortality in ICU [intensive care unit] patients,” said Dr. Shoham, section of infectious diseases, director, transplant infectious diseases, Washington Hospital Center. There was also a trend toward reduced length of hospitalization in non-ICU patients with S aureus, and in patients with blood cultures growing CNS [coagulase-negative staphylococci], regardless of location within the hospital. AdvanDx, Inc.'s PNA FISH diagnostic tests provide rapid results that enable us to optimize antimicrobial therapy, improve patient outcomes, and reduce hospital costs,” added Dr. Shoham.


Related Links:
AdvanDx, Inc.
Washington Hospital Center

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.